19365-01-6

Basic information

• Product Name: 1-Methyl-3-hydroxypyrid-2-one
• Synonyms: 1-Methyl-3-hydroxypyrid-2-one;1-methyl-3-hydroxypyridine-2-one;1-Mhpo;2(1H)-Pyridinone, 3-hydroxy-1-methyl-;1-Methyl-3-hydroxy-2(1H)-pyridinone;3-hydroxy-1-Methyl-2-pyridinone
• CAS NO: 19365-01-6
• Molecular Formula: C₆H₇NO₂
• Molecular Weight: 125.13
• Mol File: 19365-01-6.mol
• Article Data: 12

Chemical Properties

• Melting Point: 126-127 °C(Solv: ligroine (8032-32-4))
• Boiling Point: 311.6°C at 760 mmHg
• Flash Point: 142.2°C
• Appearance: /
• Density: 1.309g/cm³
• Vapor Pressure: 4.95E-05mmHg at 25°C
• Refractive Index: 1.59
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 9.03±0.58(Predicted)
• CAS DataBase Reference: 1-Methyl-3-hydroxypyrid-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Methyl-3-hydroxypyrid-2-one(19365-01-6)
• EPA Substance Registry System: 1-Methyl-3-hydroxypyrid-2-one(19365-01-6)

Safety Data

• Hazardous Substances Data: 19365-01-6(Hazardous Substances Data)

Usage

General Description

1-Methyl-3-hydroxypyrid-2-one, also known as deferiprone, is a synthetic chemical compound that is used as a chelating agent to treat iron overload in patients with thalassemia, a genetic blood disorder. Deferiprone works by binding to excess iron in the body and facilitating its removal through urine. This can help to prevent complications associated with iron overload, such as organ damage and heart problems. Deferiprone is available in oral tablet form and is often used in combination with other treatments for thalassemia. It is generally well-tolerated, with mild gastrointestinal side effects being the most commonly reported adverse reactions. Overall, deferiprone has been shown to be an effective and important tool in managing iron overload in patients with thalassemia.

InChI:InChI=1/C6H7NO2/c1-7-4-2-3-5(8)6(7)9/h2-4,8H,1H3

Upstream product

• 20928-63-6 3-methoxy-1H-pyridin-2-one 
• 74-88-4 methyl iodide 
• 16867-04-2 dihydroxypyridine 
• 497-19-8 sodium carbonate 
• 94475-64-6 3-benzyloxy-2-hydroxypyridine 
• 54955-13-4 3-methoxy-1-methyl-2(1H)-pyridone 
• 84719-32-4 3-Hydroxy-2(1H)-pyridinone 
• 94475-65-7 3-(benzyloxy)-1-methylpyridin-2(1H)-one 
• 13472-83-8 2-methoxy-3-hydroxypyridine 

Downstream Products

• 79246-92-7 3-hydroxy-1-methylpyridine-2(1H)-thione 
• 169237-39-2 3-(benzyloxy)-1-methyl-4-<(2-thioxothiazoldin-1-yl)carbonyl>-2(1H)-pyridinone 
• 1025989-29-0 benzyl 3-(benzyloxy)-1-methyl-2-oxo-1,2-dihydropyridine-4-carboxylate 
• 37463-96-0 1-Methyl-3-(phenyl-hydrazono)-piperidin-2-one 
• 169237-38-1 3-benzyloxy-4-carboxy-1-methyl-2(1H)-pyridinone 
• 35825-12-8 1-Methyl-3-hydroxy-6-morpholinomethyl-2-pyridon 
• 33341-99-0 3-hydroxy-1-methyl-2-piperidinone 

Relevant articles and documents

SMALL MOLECULE INHIBITORS OF NF-kB INDUCING KINASE

The present invention relates to compounds that inhibit NIK and pharmaceutical compositions comprising such compounds and methods of using the same. These compounds and pharmaceutical compositions are envisaged to be useful for preventing or treating diseases such as cancer (such as B-cell malignancies including leukemias, lymphomas and myeloma), inflammatory disorders, autoimmune disorders, immunodermatologic disorders such as palmoplantar pustulosis and hidradenitis suppurativa, and metabolic disorders such as obesity and diabetes.

3-Hydroxypyridin-2-thione as Novel Zinc Binding Group for Selective Histone Deacetylase Inhibition

Small molecules bearing hydroxamic acid as the zinc binding group (ZBG) have been the most effective histone deacetylase inhibitors (HDACi) to date. However, concerns about the pharmacokinetic liabilities of the hydroxamic acid moiety have stimulated rese

Synthesis of oxovanadium complexes and their apoptosis-inducing activity in leukemia cells

Vanadium complexes with different ligands were synthesized and evaluated for antiproliferative activity on U937 cells. The alkyl chain length of the ligands affected the antiproliferative activity, and two complexes - 3b and 4 - exhibited strong activities with IC50 values of 6.02 and 3.90 μM respectively. Annexin V staining and DNA ladder formation indicated that these complexes induced apoptosis in U937 cells.